Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes
15:27MINNEAPOLIS, Aug.
19, 2019 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today multiple peer-reviewed publications that provide further evidence of the safety, clinical effectiveness, and mechanisms of action of Targeted Lung Denervation (TLD) therapy in COPD. The company's dNervaŽ Lung Denervation System is a novel bronchoscopic procedure that disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity, which addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma.
Nuvaira's proprietary TLD technology has demonstrated safety and feasibility in three completed clinical studies and the company is now enrolling patients in its FDA pivotal trial, AIRFLOW-3. In a single-center ...
[Continua]
La consultazione del testo completo č riservata agli iscritti alla newsletter gratuita settimanale.
Clicca qui per accedere o per iscriverti
Clicca qui per accedere o per iscriverti
...........................................................................................................................................................................................................................................................................................................................................
Contatti | Archivio | Termini e condizioni | © Copyright 2013 lasaluteinpillole.it - supplemento alla rivista www.studiocataldi.it
...........................................................................................................................................................................................................................................................................................................................................
